Beuflox-D0.3%+0.1%

Beuflox-D 0.3%+0.1% is a fixed-dose combination of a fluoroquinolone antibiotic (ciprofloxacin) and a corticosteroid (dexamethasone), formulated as an ophthalmic (eye) preparation in Bangladesh.

Established/approved uses

• Steroid-responsive inflammatory conditions of the eye (e.g., allergic conjunctivitis, keratitis, blepharitis, blepharoconjunctivitis, iritis, cyclitis) where a bacterial ocular infection exists or there is a risk of superficial bacterial infection caused by susceptible organisms such as Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa.
• Post-operative inflammation following ocular surgery, used as an adjunct to reduce inflammation while providing antibacterial cover.

Other formulations (not marketed in Bangladesh)

In some other countries, a Beuflox-D 0.3%+0.1% combination is also marketed as an otic (ear) suspension for acute otitis externa and for acute otitis media in children with tympanostomy tubes. In Bangladesh, Beuflox-D 0.3%+0.1% is available only as an eye drop; it should not be used in the ear unless a product specifically labeled for otic use is prescribed.

Use of Beuflox-D 0.3%+0.1% should always be guided by a physician's assessment, as inappropriate steroid use in undiagnosed "red eye" can worsen certain infections.

Each mL of Beuflox-D 0.3%+0.1% ophthalmic solution contains:

• Ciprofloxacin (as hydrochloride) 3 mg (0.3% w/v)
• Dexamethasone 1 mg (0.1% w/v)

Along with sterile ophthalmic-grade excipients and a preservative to maintain sterility of the multi-dose bottle.

Beuflox-D 0.3%+0.1% is a sterile, topical ophthalmic combination product that pairs a broad-spectrum fluoroquinolone antibiotic with a potent corticosteroid in a single formulation. It is used when an eye specialist judges that both anti-inflammatory and antibacterial action are needed at the same time, such as after certain infections or eye surgery, rather than using two separate products.

The antibiotic component (ciprofloxacin) helps treat or prevent bacterial infection, while the corticosteroid component (dexamethasone) reduces the pain, redness, and swelling caused by inflammation. Because the corticosteroid component can worsen certain untreated infections (particularly viral and fungal), Beuflox-D 0.3%+0.1% is intended for short, physician-directed courses only, and not for undiagnosed or chronic eye redness.

Beuflox-D 0.3%+0.1% combines two agents with complementary mechanisms:

Ciprofloxacin (antibiotic component)

Ciprofloxacin is a fluoroquinolone that acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, and repair. This produces a bactericidal effect against a broad range of Gram-positive and Gram-negative organisms commonly implicated in ocular surface infections.

Dexamethasone (corticosteroid component)

Dexamethasone is a synthetic glucocorticoid that suppresses inflammation by inhibiting phospholipase A2, reducing production of prostaglandins and other inflammatory mediators, decreasing capillary permeability, and reducing infiltration of inflammatory cells (e.g., neutrophils) into ocular tissue. This reduces the redness, swelling, and discomfort associated with ocular inflammation.

When used together in Beuflox-D 0.3%+0.1%, the antibiotic component provides antibacterial cover while the corticosteroid component controls the inflammatory response, which is why the combination is reserved for situations where both effects are clinically warranted, under medical supervision.

• Wash hands before use. Tilt the head back, gently pull down the lower eyelid to form a small pocket, and instill the prescribed number of drops of Beuflox-D 0.3%+0.1% without letting the dropper tip touch the eye, eyelid, or any surface (to avoid contamination).
• Close the eye gently for 1–2 minutes after instillation; applying light pressure at the inner corner of the eye (punctal occlusion) can reduce systemic absorption.
• If using other eye drops or ointments at the same time, space them at least 5–10 minutes apart, with Beuflox-D 0.3%+0.1% and other products in the order advised by the physician.
• Remove contact lenses before instilling Beuflox-D 0.3%+0.1% and do not reinsert them until advised by the physician, as the preservative in the drops can be absorbed by soft lenses.
• Do not touch the dropper tip to any surface, and keep the bottle tightly closed between uses to reduce the risk of contamination.
• Discard any unused solution after completing the prescribed course, or as instructed on the product label, and do not use beyond the labeled in-use period after first opening.

Because Beuflox-D 0.3%+0.1% is applied topically to the eye, systemic absorption and clinically significant drug interactions are uncommon; however, the following points are clinically relevant:

• Other topical ophthalmic corticosteroids or NSAID eye drops: Concurrent use may have additive effects on intraocular pressure and should be supervised by an eye specialist.
• Other topical or systemic quinolone antibiotics: Concomitant use is generally unnecessary and does not add benefit; avoid combining with other fluoroquinolone products without medical advice.
• Systemic fluoroquinolones (for reference, if ciprofloxacin is also taken orally/IV for another condition): Systemic ciprofloxacin can raise theophylline levels, potentiate warfarin's anticoagulant effect, and cause reversible increases in serum creatinine with cyclosporine — these interactions are not expected with the small amount absorbed from an eye drop but are worth noting if the patient is also on systemic ciprofloxacin.

Always inform your physician or pharmacist about all other eye drops or medicines being used while on Beuflox-D 0.3%+0.1%.

Most side effects of Beuflox-D 0.3%+0.1% are local, mild, and transient. Report persistent or severe symptoms to your physician.

Common

• Transient burning, stinging, or discomfort on instillation
• Itching, redness, or a foreign-body sensation in the eye
• Blurred vision immediately after application

Less common but important (usually with prolonged use)

• Increased intraocular pressure, which can progress to glaucoma with prolonged use
• Posterior subcapsular cataract formation with long-term corticosteroid exposure
• Delayed wound/corneal healing
• Secondary ocular infection, including fungal or bacterial superinfection, due to suppression of the normal inflammatory/immune response by the corticosteroid component
• Hypersensitivity reactions (see Contraindications)

Pregnancy: There are no adequate and well-controlled studies of Beuflox-D 0.3%+0.1% in pregnant women. Beuflox-D 0.3%+0.1% should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; use only under medical supervision.

Lactation: It is not known whether topically applied ciprofloxacin or dexamethasone from Beuflox-D 0.3%+0.1% is excreted in human breast milk in clinically significant amounts. Because systemically administered corticosteroids can appear in breast milk, caution is advised; a physician should be consulted before using Beuflox-D 0.3%+0.1% while breastfeeding.

• For ophthalmic (eye) use only. Beuflox-D 0.3%+0.1% must not be injected or taken orally, and must not be used in the ear unless a product specifically labeled for otic use is prescribed.
• Prolonged use (generally beyond 10 days) requires monitoring of intraocular pressure and the lens by an ophthalmologist because of the risk of steroid-induced glaucoma and cataract.
• Prolonged corticosteroid use may also suppress the host immune response, increasing the risk of secondary ocular infection (bacterial, viral, or fungal); if a corneal ulcer or infection fails to improve, or worsens, after several days, re-evaluation (including cultures) is warranted, as this may indicate a resistant or fungal infection.
• Use with caution in patients with a history of herpes simplex keratitis, even in remission.
• Avoid wearing contact lenses during treatment (see Administration).
• Antibiotic stewardship: use Beuflox-D 0.3%+0.1% exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, to help prevent antibiotic resistance.
• As with all topical ophthalmic antibiotics, prolonged use may result in overgrowth of non-susceptible organisms, including fungi.

Ocular overdose with Beuflox-D 0.3%+0.1% (e.g., excessive drops) may cause increased local irritation, tearing, or transient blurred vision, which usually resolves; the eye can be flushed with lukewarm water if excess solution is instilled.

If Beuflox-D 0.3%+0.1% is accidentally swallowed or a large amount is ingested by a child, seek immediate medical attention or contact your nearest emergency department or a poison control center rather than attempting home treatment, as clinical judgment and monitoring may be needed.

Store at room temperature (below 30°C), protected from light and moisture; do not freeze. Keep the bottle tightly closed and out of reach and sight of children. Discard any unused solution after completing the prescribed course, or after the in-use period stated on the label, whichever comes first.

Renal impairment: No specific dose adjustment is established for Beuflox-D 0.3%+0.1% given its minimal systemic absorption when used as an eye drop; use with medical guidance in patients with significant renal disease.

Hepatic impairment: No specific dose adjustment is established; use with medical guidance in patients with significant hepatic disease.

Elderly: No specific dose adjustment is required; general precautions regarding intraocular pressure monitoring with prolonged use apply as in adults.

Pediatric: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation section.

Treatment with Beuflox-D 0.3%+0.1% is generally continued for 7–14 days depending on the indication and clinical response, and should not be used for longer than prescribed. Because of the risk of steroid-related complications (raised intraocular pressure, cataract, delayed healing, secondary infection), the physician should reassess the patient if improvement is not seen within about a week, and treatment should not be continued indefinitely or restarted without medical review.

Beuflox-D 0.3%+0.1% works through two complementary actions: ciprofloxacin kills susceptible bacteria by blocking the DNA gyrase and topoisomerase IV enzymes bacteria need to replicate their DNA, while dexamethasone reduces inflammation by inhibiting phospholipase A2 and downstream inflammatory mediators (e.g., prostaglandins), decreasing capillary permeability and inflammatory cell infiltration in ocular tissue.

C

Safety and efficacy of Beuflox-D 0.3%+0.1% ophthalmic solution have not been formally established in children below 1 year of age. In older children, it should be used only under a physician's direction, with careful attention to correct instillation technique and the same precautions regarding prolonged corticosteroid exposure (intraocular pressure, cataract, growth of resistant organisms) that apply to adults. Parents/caregivers should not use Beuflox-D 0.3%+0.1% in a child without a physician's diagnosis and prescription, since undiagnosed viral or fungal eye infections can be worsened by the corticosteroid component.